Last updated: September 6, 2026
Bremelanotide acetate, marketed as Vyleesi, is an on-demand injectable treatment for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The product received FDA approval in June 2019 and remains commercially differentiated by its melanocortin mechanism, subcutaneous autoinjector, and use before anticipated sexual activity.[1]
Vyleesi has generated modest commercial revenue relative to the size of the female sexual-health market. Its growth has been constrained by injectable administration, narrow labeling, reimbursement friction, cardiovascular warnings, and competition from oral therapy Addyi. Ownership has shifted from Palatin Technologies to AMAG Pharmaceuticals and, following AMAG’s financial distress, to Cosette Pharmaceuticals. The commercial opportunity now depends on Cosette’s ability to rebuild physician awareness, expand access, and improve patient persistence.
What is bremelanotide acetate and how does Vyleesi work?
Bremelanotide is a melanocortin receptor agonist, with activity primarily at MC1R and MC4R. Vyleesi is supplied as a 1.75-mg subcutaneous autoinjector used at least 45 minutes before anticipated sexual activity. Patients may use no more than one dose in 24 hours and no more than eight doses per month.[1]
The FDA-approved indication is narrow:
| Attribute |
Vyleesi |
| Active ingredient |
Bremelanotide acetate |
| Brand |
Vyleesi |
| FDA application |
NDA 210557 |
| Sponsor at approval |
AMAG Pharmaceuticals |
| Current commercial owner |
Cosette Pharmaceuticals |
| Initial FDA approval |
June 21, 2019 |
| Indication |
Acquired, generalized HSDD in premenopausal women |
| Administration |
Subcutaneous autoinjector |
| Dosing |
1.75 mg as needed, at least 45 minutes before activity |
| Maximum use |
One dose per 24 hours; eight doses per month |
| Mechanism |
Melanocortin receptor agonism |
| Controlled-substance status |
Not a controlled substance |
The label excludes women with cardiovascular disease or uncontrolled hypertension. Frequent adverse reactions include nausea, flushing, injection-site reactions, headache, and transient increases in blood pressure.[1]
How large is the bremelanotide market?
The addressable market is materially larger than current treated demand. HSDD affects a meaningful minority of women, but the FDA label limits Vyleesi to premenopausal patients with acquired and generalized symptoms. That restriction removes postmenopausal patients, women with situational loss of desire, and patients whose symptoms are primarily attributable to relationship, psychiatric, medication-related, or medical causes.
The commercial market is therefore defined by four filters:
- A confirmed HSDD diagnosis.
- Premenopausal status.
- Willingness to use an injection before sexual activity.
- Ability to obtain reimbursement or pay out of pocket.
The market is also dependent on diagnosis. HSDD is underdiagnosed, and many patients seek treatment through primary care, gynecology, sexual-medicine specialists, telehealth platforms, or direct-to-consumer channels. Product adoption requires education of prescribers who may not routinely screen for sexual desire disorders.
How does Vyleesi compare with Addyi?
Vyleesi competes primarily with flibanserin, marketed as Addyi. The products have different administration schedules and mechanisms.
| Commercial factor |
Vyleesi |
Addyi |
| Active ingredient |
Bremelanotide |
Flibanserin |
| Route |
Subcutaneous injection |
Oral tablet |
| Use |
As needed before sexual activity |
Daily at bedtime |
| FDA population |
Premenopausal women |
FDA labeling has expanded beyond the original premenopausal restriction |
| Mechanism |
Melanocortin receptor agonist |
Serotonin receptor modulation |
| Main adoption barrier |
Injection, nausea, blood-pressure warnings |
Daily adherence, alcohol and drug-interaction restrictions |
| Generic or biosimilar exposure |
Small-molecule generic risk |
Small-molecule generic risk |
| Commercial positioning |
Intermittent, event-driven treatment |
Continuous oral treatment |
Vyleesi’s as-needed schedule is attractive for patients who reject daily medication. Its injection requirement is a major counterweight. Addyi has a simpler route of administration but requires continued daily use and carries central nervous system and interaction restrictions.[1][2]
Neither product has achieved the scale of mainstream primary-care therapies. The category remains dependent on specialist prescribing, patient education, insurance coverage, and direct-to-consumer marketing.
What is the financial trajectory of Vyleesi?
Vyleesi produced an early launch followed by limited commercial scale. AMAG reported approximately $18 million in Vyleesi net product sales for 2020, with revenue affected by launch execution, patient access, and the COVID-19 disruption to physician visits.[3] Subsequent disclosures indicated that the product remained a small contributor to the broader AMAG portfolio.
Vyleesi financial timeline
| Period |
Financial and commercial event |
| 2017 |
AMAG acquired North American rights from Palatin |
| June 2019 |
FDA approved Vyleesi |
| 2019 |
Commercial launch began |
| 2020 |
AMAG reported approximately $18 million in Vyleesi net product sales |
| 2021-2022 |
Product remained commercially subscale while AMAG faced financial pressure |
| 2023 |
Cosette acquired Vyleesi and other AMAG assets |
| 2024 onward |
Cosette controlled commercial development; standalone revenue was not publicly reported |
Vyleesi’s revenue profile reflects a specialty product with low refill frequency. A patient using the maximum eight doses per month may still purchase fewer units than a daily-use chronic therapy. Discontinuation after nausea, inadequate efficacy, or lack of reimbursement reduces recurring revenue.
The principal financial variables are:
- New patient starts.
- Prescription conversion after diagnosis.
- Insurance approval rates.
- Copayment assistance.
- Refill persistence.
- Average doses used per month.
- Specialty pharmacy and telehealth penetration.
- Promotional spending per new prescription.
- Net price after rebates and assistance.
Cosette is privately held and does not provide the same level of product-specific public reporting as a listed pharmaceutical company. The market therefore lacks a current, audited Vyleesi revenue series after the AMAG transaction. The acquisition gives Cosette the opportunity to reset pricing, patient-support programs, distribution, and promotional strategy, but it also reduces transparency for investors and licensing counterparties.
Who owns Vyleesi and what licensing deals shaped the product?
Palatin developed bremelanotide and licensed North American commercial rights to AMAG Pharmaceuticals. AMAG obtained rights to commercialize Vyleesi in the United States and Canada while Palatin retained interests outside the licensed territory and economic rights specified in the collaboration agreement.[4]
AMAG’s acquisition of Vyleesi rights was strategically important because the company had an established women’s-health portfolio, including Intrarosa. The product later became exposed to AMAG’s balance-sheet problems. AMAG entered bankruptcy proceedings in 2022, and Cosette acquired selected assets, including Vyleesi, in 2023.[5]
Ownership structure
| Period |
Rights holder or commercial sponsor |
| Development period |
Palatin Technologies |
| 2017-2022 |
AMAG Pharmaceuticals, North American commercial rights |
| 2023 onward |
Cosette Pharmaceuticals, acquired commercial assets |
| Ex-U.S. rights |
Subject to separate territorial arrangements and licenses |
The ownership transition matters because Vyleesi’s economics are not determined solely by prescription demand. Royalty obligations, milestone rights, manufacturing costs, promotional commitments, and territorial rights affect the net value available to the commercial owner.
When does Vyleesi lose regulatory exclusivity?
Vyleesi received five years of new chemical entity exclusivity beginning with FDA approval in June 2019. That period expired in June 2024, subject to the statutory treatment of any applicable pediatric extension or regulatory adjustments.[6]
The end of NCE exclusivity allows an ANDA applicant to pursue a generic pathway, but it does not automatically eliminate patent barriers. Generic entry depends on the patents listed in the FDA Orange Book, the applicant’s Paragraph IV certification strategy, litigation, and any settlement restricting launch.
Key FDA exclusivity dates
| Protection |
Date or status |
| FDA approval |
June 21, 2019 |
| Five-year NCE exclusivity |
Expired in June 2024 |
| Orange Book patent protection |
Potentially extends beyond regulatory exclusivity |
| Biosimilar exclusivity |
Not applicable |
| Generic pathway |
ANDA, subject to listed patents and litigation |
Vyleesi is a chemically synthesized small molecule. Biosimilar competition does not apply. The relevant future threat is an abbreviated new drug application for generic bremelanotide, not a 351(k) biosimilar application.
What patents protect bremelanotide acetate?
Vyleesi’s protection has historically relied on a combination of active-ingredient, formulation, delivery-device, and method-of-use rights. The commercial value of the estate depends on whether a generic applicant can design around the listed claims while maintaining the same route, dose, and indication.
The FDA Orange Book record for NDA 210557 is the controlling source for patents that may trigger certification and litigation under the Hatch-Waxman framework.[7] Publicly associated patent families have included rights directed to bremelanotide formulations and therapeutic use. The principal patent risks are:
Formulation patents
Formulation claims can cover concentration, excipients, pH, stability, and injectable composition. These claims are commercially important because Vyleesi is supplied as a ready-to-use autoinjector rather than as a conventional tablet or vial.
A generic applicant may challenge formulation patents through a Paragraph IV certification or seek a formulation design that avoids the asserted claims. Manufacturing complexity and stability requirements can raise technical barriers even when the active ingredient itself is no longer protected.
Method-of-use patents
Method claims may cover treatment of female sexual dysfunction, dosing before sexual activity, or patient selection. Their enforceability depends on claim scope, induced-infringement evidence, labeling, and the prescribing behavior of generic manufacturers.
Method-of-use patents can delay generic commercialization when the approved label includes the patented indication. They are less effective when a generic applicant can use a skinny label that removes the patented use and physicians still prescribe the product for that indication.
Device and combination protection
The autoinjector and drug-device combination may create manufacturing and regulatory barriers. Device claims do not always prevent a competing generic from using a different injector, syringe, or delivery configuration. Their value depends on whether the device is essential to the approved product and whether the generic must demonstrate equivalent performance.
What Paragraph IV challenges and litigation affect Vyleesi?
Publicly visible commercial litigation has been limited compared with large oncology, diabetes, and immunology products. The absence of major reported Paragraph IV litigation does not establish that the estate is unchallenged. ANDA applicants can file certifications that lead to confidential negotiations, declaratory actions, or litigation after patent-listing changes.
A generic applicant would likely evaluate:
- Whether NCE exclusivity has expired.
- Which Orange Book patents remain unexpired.
- Whether listed patents cover the active ingredient, formulation, method of use, or device.
- Whether a Paragraph IV filing triggers a 30-month stay.
- Whether a non-infringement or invalidity position is stronger than a design-around.
- Whether commercial launch economics justify litigation.
No publicly established Vyleesi settlement date or authorized-generic launch date has become a central market event. The commercial impact of any future settlement would depend on the agreed launch date, royalties, and scope of the generic label.
How strong is the Vyleesi patent estate?
The estate is stronger against a direct copy of the marketed injectable product than against all possible forms of bremelanotide competition.
| Protection layer |
Relative commercial value |
Main vulnerability |
| Active-ingredient rights |
Lower after regulatory exclusivity ends |
Expiration and invalidity challenges |
| Injectable formulation |
Medium to high |
Design-around formulations |
| Autoinjector or delivery system |
Medium |
Alternative device architecture |
| Method of use |
Medium |
Skinny-label strategy and inducement disputes |
| Manufacturing know-how |
Medium |
Process replication and regulatory comparability |
| Brand and patient-support infrastructure |
Medium |
Generic substitution and lower-price competition |
The estate’s strongest practical barrier may be the combination of formulation, device, regulatory documentation, and market access rather than a single composition-of-matter patent. That barrier can preserve branded sales after NCE expiry, but it does not guarantee long-term exclusivity.
What generic launch scenarios exist for bremelanotide?
Three scenarios are commercially relevant.
Scenario 1: No near-term generic launch
A generic applicant may conclude that the market is too small to justify formulation development and Paragraph IV litigation. Vyleesi would retain effective exclusivity despite the expiration of NCE protection.
Scenario 2: First generic launch after patent settlement
Cosette could settle with an ANDA applicant for a future entry date. This outcome would create a defined erosion period and could preserve substantial branded revenue before launch.
Scenario 3: Litigation-driven early entry
A successful Paragraph IV challenge could produce an earlier launch. Revenue erosion would likely be rapid because generic substitution is easier for a small-molecule product than for a biologic. The impact would still depend on pharmacy substitution, payer formulary placement, and whether the generic uses an equivalent autoinjector.
What FDA regulatory issues affect Vyleesi’s growth?
The FDA label limits broad market expansion. The most important regulatory constraints are cardiovascular safety, nausea, blood-pressure elevation, and the premenopausal HSDD population.[1]
Vyleesi is not approved for:
- Men.
- Postmenopausal women.
- Performance enhancement.
- Infertility treatment.
- General sexual dysfunction without an HSDD diagnosis.
- Routine daily use.
The product also requires disciplined patient selection. Blood-pressure monitoring, contraindication screening, and counseling on nausea may reduce prescribing by general practitioners.
A label expansion could increase the addressable market, but it would require clinical evidence and FDA review. No approved broad-label expansion has transformed Vyleesi into a general female sexual-health product.
What revenue exposure does Vyleesi create for Cosette?
Vyleesi is unlikely to be a major revenue concentration risk for Cosette relative to a large pharmaceutical company, but it can be strategically useful as a branded women’s-health asset. Its value lies in platform fit, prescriber relationships, and potential cross-selling with other women’s-health products.
For Cosette, the product has four financial advantages:
- Existing FDA approval.
- Established safety and efficacy package.
- Recognized brand in a limited competitive field.
- Potential for commercial relaunch without full development risk.
The disadvantages are equally clear:
- Low historical sales scale.
- High patient-acquisition cost.
- Injectable administration.
- Narrow patient population.
- Reimbursement variability.
- Patent and generic uncertainty.
- Limited public financial disclosure.
The most realistic trajectory is a stable specialty product with moderate relaunch upside, not rapid blockbuster growth.
How does Vyleesi compare with other women’s-health assets?
Vyleesi has a narrower clinical use than contraceptives, hormone therapies, menopause products, and fertility drugs. Those categories generally have larger treated populations and more predictable prescribing. Vyleesi’s advantage is differentiation in a category with limited FDA-approved pharmacologic options.
Its commercial performance will depend less on broad epidemiological prevalence than on the company’s ability to create a diagnosis-and-treatment pathway. That requires targeted specialists, telehealth access, patient support, and reimbursement execution.
Key Takeaways
- Bremelanotide acetate is marketed as Vyleesi for acquired, generalized HSDD in premenopausal women.
- FDA approval occurred on June 21, 2019.
- Vyleesi’s five-year NCE exclusivity expired in June 2024.
- The product’s commercial barriers are injection administration, nausea, cardiovascular warnings, narrow labeling, and reimbursement.
- AMAG reported approximately $18 million in Vyleesi net product sales for 2020.
- Cosette acquired Vyleesi after AMAG’s financial distress and now controls the commercial opportunity.
- Vyleesi is exposed to generic competition, not biosimilar competition.
- Formulation, device, method-of-use, and manufacturing rights may extend effective protection beyond NCE expiry.
- Publicly disclosed Paragraph IV litigation and settlement activity has not materially reshaped the market.
- The near-term value proposition is a specialty relaunch and revenue stabilization rather than blockbuster expansion.
FAQs
Is bremelanotide acetate the same as flibanserin?
No. Bremelanotide is the active ingredient in Vyleesi and is administered by subcutaneous injection as needed. Flibanserin is the active ingredient in Addyi and is administered orally on a recurring schedule.
Can men use Vyleesi?
Vyleesi is not FDA-approved for men. Its approved indication is limited to premenopausal women with acquired, generalized HSDD.
Does Vyleesi have biosimilar competition?
No. Vyleesi contains a chemically synthesized small molecule. Future competition would come through an ANDA for generic bremelanotide, not through the biosimilar pathway.
What is the biggest commercial risk for Vyleesi?
The largest commercial risk is limited patient conversion and persistence caused by the injectable route, adverse effects, narrow eligibility, and inconsistent reimbursement.
Could Vyleesi become a blockbuster drug?
A blockbuster outcome would require substantial expansion in diagnosis, reimbursement, prescriber adoption, or FDA-approved use. Based on its historical sales scale and current label, Vyleesi is better characterized as a specialty women’s-health asset with relaunch potential.
References
-
U.S. Food and Drug Administration. (2019). Vyleesi (bremelanotide injection) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022). Addyi (flibanserin) prescribing information. FDA.
-
AMAG Pharmaceuticals, Inc. (2021). Annual report on Form 10-K for the year ended December 31, 2020. U.S. Securities and Exchange Commission.
-
Palatin Technologies, Inc. (2017). Palatin and AMAG Pharmaceuticals enter licensing agreement for bremelanotide. Company announcement.
-
U.S. Bankruptcy Court for the District of Delaware. (2023). AMAG Pharmaceuticals bankruptcy and asset-sale filings.
-
U.S. Food and Drug Administration. (2024). New chemical entity exclusivity and regulatory exclusivity provisions. FDA.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book, NDA 210557. FDA.
